(24) and by doing so would position the Xistcoated DNA away from the actively transcribed Xist transcription locus. This would enable other DNA regions on the X chromosome, which are physically linked to these tethered regions, to be brought into closer spatial proximity of the Xist transcription locus. In this way, Xist and its silencing factors can spread to these newly accessible DNA regions on the X chromosome.
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A therosclerosis initiates when oxidized lipoprotein infiltrates the subendothelial space of arteries, often due to aberrantly elevated levels of apolipoprotein B-containing lipoproteins in the blood (1) . Chemotactic signals arising from activated endothelium and vascular smooth muscle attract circulating monocytes that develop into lipid-loaded foamy macrophages, a subset of which adopt a proinflammatory phenotype through a mechanism that is not fully understood. The proinflammatory signals lead to additional rounds of monocyte recruitment and accumulation of other inflammatory cells (including T and B cells, dendritic cells, and mast cells), allowing initial lesions, often termed "fatty streaks," to increase in size and develop into plaques (2) . Plaque stability, rather than absolute size, determines whether atherosclerosis is clinically silent or pathogenic because unstable plaques can rupture and produce vesseloccluding thrombosis and end-organ damage. Stable plaques have a relatively thick fibrous cap, which largely consists of vascular smooth muscle cells (VSMCs) and extracellular matrix components, partitioning soluble clotting factors in the blood from thrombogenic molecules in the plaque (3). In advanced disease, plaques destabilize when elevated local matrix metalloprotease production degrades the fibrous cap, increasing the risk of lesion rupture and subsequent thrombosis.
Advanced plaques contain cells with markers of senescence, a stress response that entails a permanent growth arrest coupled to the robust secretion of numerous biologically active molecules and is referred to as the senescence-associated secretory phenotype (SASP). The senescence markers include elevated senescence-associated b-galactosidase (SA b-Gal) activity and p16
Ink4a
, p53, and p21 expression (4, 5) . However, whether and how senescent cells contribute to atherogenesis remains unclear (6, 7) . Human plaques contain cells with shortened telomeres, which predispose cells to undergo senescence (8) . Consistent with a proatherogenic role of senescence is the observation that expression of a loss-offunction telomere-binding protein (Trf2) in VSMCs accelerates plaque growth in the ApoE -/-mouse model of atherosclerosis, although in vivo evidence for increased senescence in plaques was not provided. On the other hand, mice lacking core components of senescence pathways, such as p53, p21, or p19 Arf (7, (9) (10) (11) , show accelerated atherosclerosis, implying a protective role for senescence. Studies showing that human and mouse polymorphisms that reduce expression of p16 Ink4a and p14
Arf (p19 Arf in mice) correlate with increased atheroma risk support this conclusion (7, 12, 13 ;3MR mice fed a HFD for 88 days and then treated short term with GCV had low levels of SA b-Gal activity compared with Ldlr -/-mice ( fig. S1C ), indicating efficient clearance of senescent cells. Examination of the plaques by transmission electron microscopy (TEM) revealed that three morphologically distinct cell typeselongated, vacuolated cells located in the endothelial layer; spindly foam cells with histological properties of VSMCs; and large foamy cells resembling lipid-loaded macrophages-produced X-galactosidase (X-Gal) crystals (Fig. 1A) . We refer to these cells as endothelial-like, foamy VSMClike, and foamy macrophage-like cells, respectively, because cells within plaques change shape and lineage markers, precluding accurate assessment of cell origin (15, 16) . All three senescent cell types were efficiently eliminated by treatment with GCV (Fig. 1A) .
To assess the impact senescent cells have on plaque development, we placed 10-week-old
;3MR mice on a HFD for 88 days and simultaneously treated them with GCV or vehicle during this period (Fig. 1B) to intermittently remove p16
Ink4a+ cells. To control for potential effects of GCV, independent of 3MR expression, we also examined GCV-treated Ldlr -/-mice on a HFD. En face staining of descending aortas with Sudan IV revealed that plaque burden was~60% lower in GCV-treated Ldlr -/-;3MR mice than in vehicle-treated Ldlr Data represent mean ± SEM (error bars) [biological n is indicated on graphs and refers to individual plaques in (A) (one per mouse) and aortas in (C)]. *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired two-tailed t tests with Welch's correction). ;3MR mice were highly elevated compared with levels in LFD-fed controls, with no differences between the distinct HFD-fed cohorts ( fig. S4I) . Thus, the atheroprotective effect in GCV-treated Ldlr -/-;3MR mice is due to the killing of p16
GCV-treated Ldlr
Ink4a+ senescent cells rather than changes in feeding habits, blood lipids, or circulating immunocytes. Reductions in plaque burden, number, and size observed with p16-3MR were reproducible with two independent transgenic systems [INK-ATTAC ( fig. S5) (18, 19) and INK-Nitroreductase (NTR) ( fig. S6 )] designed to kill p16
Ink4a+ senescent cells through distinct mechanisms, as well as with the senolytic drug ABT263, which inhibits the anti-apoptotic proteins Bcl-2 and Bcl-xL and selectively kills senescent cells ( fig. S7) (20) .
To investigate how senescent cells drive plaque initiation and growth, we focused on atherogenesis onset at lesion-prone sites of the vasculature (21) . After just 9 days on an atherogenic diet, Ldlr -/-mice had overtly detectable fatty-streak lesions solely in the inner curvature of the aortic arch ( Fig. 2A and fig. S8A) . Surprisingly, these early lesions were highly positive for SA b-Gal activity ( Fig. 2A) . By contrast, Ldlr -/-mice containing 3MR and treated daily with GCV during the 9-day HFD-feeding period had low levels of SA b-Gal activity and much smaller fatty streaks ( Fig. 2A) . Histological examination by TEM of the SA b-Gal-stained samples revealed that fatty streaks of HFD-fed Ldlr −/− mice consisted of foci of foam cell macrophages arranged in mono-or multilayers (Fig. 2, B and C). The lesions had intact elastic fibers and no fibrous cap. X-Gal crystals were detectable exclusively in foam cell macrophages, irrespective of lesion size (Fig. 2 , B and D). Foam cell macrophages in foci of 9-day lesions of Ldlr -/-;3MR mice receiving daily, highdose GCV were rarely arranged in multilayers and had a much lower incidence of crystals (Fig. 2 ;3MR mice on a 12-day HFD and treated with GCV for the last 3 days. Scale bars: 1 mm (A) and (E); 2 mm (B); and 500 nm [(B), insets]. Bar graphs represent mean ± SEM (error bars) [biological n is indicated directly on all graphs and refers to individual aortic arches in (A) and (C) to (E) or dissected aortic arch inner curvatures in (F)]. *P < 0.05; **P < 0.01; ***P < 0.001 (unpaired two-tailed t tests with Welch's correction). ;3MR mice and then administered highdose GCV for 3 days while continuing to feed the mice a HFD. Short-term clearance of senescent cells markedly reduced streak size and SA b-Gal positivity (Fig. 2E) . TEM images showed that cleared foci were drastically remodeled, with acellular debris retained in the subendothelium and few foamy macrophages containing X-Gal crystals ( fig. S8, D and E) . RT-qPCR revealed a stark reduction in p16
Ink4a and SASP components (including Mmp3, Mmp13, Il1a, and Tnfa), as well as two key molecular drivers of monocyte recruitment (the chemokine Mcp1 and the leukocyte receptor Vcam1), whose expression is partly driven by Tnfa (Fig. 2F) . These data suggest that subendothelial senescent foamy macrophages arising in early lesions enhance Tnfamediated Vcam1 expression, as well as the Mcp1 gradient, to perpetuate monocyte recruitment from the blood.
Next, we examined the role of senescent cells in the maturation of benign plaques to complex advanced lesions. Although mouse models for atherosclerosis do not develop clinical symptoms associated with plaque ruptures, plaque maturation in these mice can be studied using surrogate markers of plaque instability, including fibrous cap thinning (22, 23) , decreased collagen deposition, elastic fiber degradation, and plaque calcification (24) . To assess the effect of senescent cell clearance on the maturation of existing plaques, we employed late-disease senescent cell clearance protocols in which we placed Ldlr /-and Ldlr -/-;3MR mice on a HFD for 88 days to create plaques, followed by 100 days of GCV treatment. During GCV treatment, mice were fed a HFD or LFD to promote continued plaque advancement or stasis, respectively (Fig. 3A and  fig. S9 ). Ldlr -/-;3MR mice maintained on the HFD and receiving GCV showed attenuated disease progression, as evidenced by a lower plaque number and size compared with GCV-treated Ldlr -/-or vehicle-treated Ldlr -/-;3MR controls (Fig.  3A) . Whereas plaques of GCV-treated Ldlr -/-;3MR mice on a LFD had markedly reduced Sudan IV staining compared with plaques of control mice, the lesion-covered aortic area did not change ( fig. S10A ), even though 3MR-mediated senescent cell killing was confirmed by SA b-Gal staining ( fig. S10B ) and RT-qPCR for senescence markers (Fig. 3B) . Regardless of diet, senescent cell clearance reduced expression of inflammatory cytokines (Fig. 3B) and monocyte recruitment factors (fig.  S10C ). GCV treatment decreased expression of matrix metalloproteases linked to plaque destabilization, including Mmp3, Mmp12, and Mmp13 (25, 26) (Fig. 3B) , which suggests that senescent cell elimination stabilizes the fibrous cap.
To investigate this and other features of plaque maturation, we conducted histopathology on plaques collected from the above cohorts. When Ldlr -/-mice originally fed a HFD for 88 days were left on the diet for an additional 100 days, their descending aorta plaques showed reduced cap thickness, diminished collagen content (by Masson's trichrome staining), and more disrupted aortic elastic fibers (by Voerhoff von Gieson staining) in comparison with those of LFD-fed mice (Fig. 4, A and B, and fig. S11 ). In contrast, all of these markers of plaque instability were decreased with clearance of p16 Ink4a+ cells, regardless of diet, during the 100-day GCV treatment period. Similarly, clearance of p16
Ink4a+ cells increased cap thickness and collagen content in brachiocephalic arteries from mice reverted to LFD (fig. S12) . We extended these studies by switching Ldlr S13F ) (27) . Clearance markedly reduced monocyte attachment to plaque-adjacent endothelium ( fig. S13G ), thus supporting our conclusion from early fatty-streak experiments that enhanced monocyte chemotaxis may partially explain the proatherogenic nature of senescent cells. These results strongly suggest that eliminating p16 Ink4a+ cells promotes plaque stability.
To further investigate the mechanism by which senescent cells drive atherogenesis, we tested the possibility that senescent cells in plaques express proatherogenic factors. We dissected lesionbearing tissue from HFD-fed Ldlr for analysis by RT-qPCR (Fig. 4C) . Senescent cells expressed a broad spectrum of proatherogenic factors, including Il1a, Tnfa, Mmp3, Mmp12, Mmp13, Mcp1, and Vcam1 (Fig. 4C) that senescent cells are uniformly deleterious throughout atherogenesis. Very early fatty streaks contain abundant senescent foam cell macrophages, which create an environment conducive to further lesion growth by up-regulating inflammatory cytokines and monocyte chemotactic factors. Removal of p16 Ink4a+ foamy macrophages from fatty streaks led to marked lesion regression. In contrast, advanced plaques contain three morphologically distinct senescent cell types that not only drive lesion maturation through inflammation and monocyte chemotaxis but also promote extracellular matrix degradation. Clearing senescent cells from advanced lesions inhibits both plaque growth and maladaptive plaque remodeling processes associated with plaque rupture, including fibrous cap thinning and elastic fiber degeneration. Furthermore, senescent cells in lesions show heightened expression of key SASP factors and effectors of inflammation, monocyte chemotaxis, and proteolysis, including Il1a, Mcp1, Mmp12, and Mmp13. These data suggest that senescent cells can directly influence core proatherogenic processes through specific secreted factors. By comparison, the expression of other factors such as Mmp3, Tnfa, and Vcam1 is reduced with senolysis, but these factors are not enriched in p16
Ink4a+ cells, which implies that senescent cells also can influence the proatherogenic milieu indirectly. Collectively, our results show that senescent cells drive atherosclerosis at all stages through paracrine activity and raise the possibility that druglike molecules that remove senescent cells from patients without toxic side effects could contribute to therapeutic management of the disease.
